Mouse Anti-OPN Recombinant Antibody (clone 23C3) (CAT#: PABL-291)

Figure 1 Reactivity of the mAb with various forms of OPN. Lane 1, Human OPN; lane 2, murine OPN; lane 3, supernatant from human cell line MDA-MB-435 in culture; lane 4, synovial fluid from patients with rheumatoid arthritis.

Fan, K., Dai, J., Wang, H., Wei, H., Cao, Z., Hou, S.,... & Xu, H. (2008). Treatment of collagen‐induced arthritis with an anti‐osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 2041-2052.

Figure 2 Inhibition of migration of splenic monocytes from arthritic mice by anti-OPN mAb in the absence (bovine serum albumin [BSA] control) or presence of the indicated concentrations of recombinant OPN (left) or in the presence of 10 g/ml OPN and mAb 23C3, mAb F8E11, polyclonal anti-OPN antibody (Poly Ab), or isotype-matched control Ig antibodies at the indicated concentrations (right).

Fan, K., Dai, J., Wang, H., Wei, H., Cao, Z., Hou, S.,... & Xu, H. (2008). Treatment of collagen‐induced arthritis with an anti‐osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 2041-2052.

Figure 3 Suppression of the development of collagen-induced arthritis (CIA) by anti-OPN mAb.

a, Clinical scores for developing CIA in mice treated on days 0, 2, 4, 6, 8, and 10 after immunization with anti-OPN mAb doses of 50, 100, and 200 g per mouse. Results are representative of 2 experiments; bars show the mean and SEM results from 15 mice per group. b, Incidence of CIA in mice treated after immunization with doses of 200 g per mouse. c, Histologic features of the arthritic joints after anti-OPN treatment at doses of 200 g per mouse. Sections of ankle joints in the fore and hind paws were stained with hematoxylin and eosin (A–H), and representative histologic images of the hind paws are shown for normal mice (A and E), arthritic mice (B and F), mAb 23C3–treated mice (C and G), and mAb F8E11–treated mice (D and H). d, Expression of cytokines in the ankle joints on day 14 after the second immunization. Res

Fan, K., Dai, J., Wang, H., Wei, H., Cao, Z., Hou, S.,... & Xu, H. (2008). Treatment of collagen‐induced arthritis with an anti‐osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 2041-2052.

Figure 4 Amelioration of established collagen-induced arthritis (CIA) and reduction of type II collagen (CII)–specific autoantibody production by anti-OPN mAb. a, Clinical scores for established CIA in mice treated on days 7, 9, 11, 13, and 15 after the second immunization. b, Titers of anti-CII total Ig, IgG1, and IgG2a, measured after treatment of CIA.

Fan, K., Dai, J., Wang, H., Wei, H., Cao, Z., Hou, S.,... & Xu, H. (2008). Treatment of collagen‐induced arthritis with an anti‐osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 2041-2052.